Axsome Therapeutics Inc., a US-based biopharmaceutical firm, is dedicated to the creation of innovative treatments for central nervous system (CNS) disorders. The company has a strong commercial product portfolio that includes Auvelity (dextromethorphan-bupropion), an N-methyl-D-aspartate receptor antagonist, and Sunosi (solriamfetol), aimed at the treatment of major depressive disorder and excessive daytime sleepiness, respectively. Axsome Therapeutics is also actively developing AXS-05, currently in Phase III clinical trials to treat Alzheimer's disease agitation, and a medication which has completed Phase II clinical trials for smoking cessation, among other conditions. Other investigational medicines include AXS-07 for the acute treatment of migraine, AXS-12 for narcolepsy treatment, AXS-14 for fibromyalgia treatment, and Solriamfetol as a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed Phase 2 trials for treating attention-deficit/hyperactivity disorder. The company has a research collaboration agreement with Duke University to evaluate AXS-05 for smoking cessation. Incorporated in 2012 and located in New York, Axsome Therapeutics Inc. is actively advancing the fight against CNS disorders with cutting-edge treatments.
Axsome Therapeutics's ticker is AXSM
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at Axsome Therapeutics
It is axsome.com
Axsome Therapeutics is in the Healthcare sector
Axsome Therapeutics is in the Biotechnology industry
The following five companies are Axsome Therapeutics's industry peers: